Study Evaluating The Potential Effect of Lansoprazole On The Pharmacokinetics Of Bosutinib in Healthy Subjects
Information source: Wyeth
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Bosutinib (Drug); Lansoprazole (Drug)
Phase: Phase 1
Status: Not yet recruiting
Sponsored by: Wyeth Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth
Overall contact:
Trial Manager, Email: clintrialparticipation@wyeth.com
Summary
The purpose of this study is to see if there is an effect on the pharmacokinetics of
bosutinib when administered with lansoprazole.
Clinical Details
Official title: A Study to Examine the Potential Effect of Lansoprazole on the Pharmacokinetics of Bosutinib When Administered Concomitantly to Healthy Subjects
Study design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Pharmacokinetics Study
Primary outcome: Pharmacokinetics as measured by Cmax, AUC, tmax, t1/2
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion criteria:
- Healthy men and women of nonchildbearing potential, between the ages of 18 to 50
years old.
Exclusion criteria:
- Any cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine,
immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
Locations and Contacts
Trial Manager, Email: clintrialparticipation@wyeth.com Additional Information
Starting date: September 2009
Ending date: September 2009
Last updated: August 4, 2009
|
